How oft is the Lu-PSMA treatment conducted? The usual cycle consists of 3 sessions with 6 to 8 weeks interval in-between. Our more restrictive treatment regimen of initial 3 cycles with an interval of only 4 weeks in-between demonstrated >80% response rates even in heavily pre-treated patients. This treatment does not care, “where” the metastases are: lymph nodes, bone, lungs, liver or even tumor in the prostate region itself. The usual “victims” of PSMA ligands, the salivary glands and kidneys, are not significantly affected under this regimen. Read more here.

Check other scientific investigations of our team on the topic.

Fluorine-18 is a commonly used isotope utilized for conducting PSMA-PET/CT to stage prostate cancer, due to its longer half-life and higher production capacity as compared to Gallium-68. The latest study, however, has demonstrated superiority of Ga-68, because of the focal unspecific uptake of F-18 in the bones of ribs and pelvis. Without additional follow-up exams or any morphological correlates, this may be misinterpreted as bone metastasis. While nonspecific uptake in other tissues and physiologic uptake in the ganglia can be filtered out, unspecific bone uptake tends to lead to false interpretation and misdiagnosis. Bone metastases do occur in 10% of patients with the newly diagnosed prostate cancer, and 80-90% of patients in the advanced stage. Over-staging the patient may result in inadequate therapy decisions, especially in case of early biochemical recurrence. Read more.

On Friday, 17 September 2021, Novartis announced further positive findings from the VISION trial: ¹⁷⁷Lu-PSMA-617 therapy delays worsening of physical functioning and the onset of pain symptoms in patients with mCRPC. Hence, beyond extending overall survival and progress-free period, this Breakthrough Therapy also improves health-related quality of life. Read more

Markus Hartenbach remporte le prix du jeune chercheur du conseil d'oncologie de l'association nord-américaine de médecine nucléaire

Équipe de chercheurs dirigée par Ass. Prof. Dr. Markus Hartenbach a pu démontrer la supériorité du TEP PSMA dans le diagnostic de la récidive biochimique du cancer de la prostate, même à de faibles niveaux de PSA.

European Journal of Nuclear Medicine and Molecular Imaging

Équipe de chercheurs dirigée par Prof. Dr. Markus Hartenbach a pu démontrer la valeur diagnostique exceptionnelle du TEP/IRM PSMA dans le cancer de la prostate confirmé par biopsie.